Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 3
2016 1
2017 2
2018 3
2019 3
2021 1
2022 2
2023 1
2024 3
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
RNA aggregates harness the danger response for potent cancer immunotherapy.
Mendez-Gomez HR, DeVries A, Castillo P, von Roemeling C, Qdaisat S, Stover BD, Xie C, Weidert F, Zhao C, Moor R, Liu R, Soni D, Ogando-Rivas E, Chardon-Robles J, McGuiness J, Zhang D, Chung MC, Marconi C, Michel S, Barpujari A, Jobin GW, Thomas N, Ma X, Campaneria Y, Grippin A, Karachi A, Li D, Sahay B, Elliott L, Foster TP, Coleman KE, Milner RJ, Sawyer WG, Ligon JA, Simon E, Cleaver B, Wynne K, Hodik M, Molinaro AM, Guan J, Kellish P, Doty A, Lee JH, Massini T, Kresak JL, Huang J, Hwang EI, Kline C, Carrera-Justiz S, Rahman M, Gatica S, Mueller S, Prados M, Ghiaseddin AP, Silver NL, Mitchell DA, Sayour EJ. Mendez-Gomez HR, et al. Among authors: sayour ej. Cell. 2024 May 9;187(10):2521-2535.e21. doi: 10.1016/j.cell.2024.04.003. Epub 2024 May 1. Cell. 2024. PMID: 38697107
In client-owned canines with terminal gliomas, RNA-LPAs improved survivorship and reprogrammed the TME, which became "hot" within days of a single infusion. ...These data support RNA-LPAs as a new technology that simultaneously reprograms the TME while eliciting rap …
In client-owned canines with terminal gliomas, RNA-LPAs improved survivorship and reprogrammed the TME, which became "hot" within day …
mRNA aggregates harness danger response for potent cancer immunotherapy.
Mendez-Gomez HR, DeVries A, Castillo P, Stover BD, Qdaisat S, Von Roemeling C, Ogando-Rivas E, Weidert F, McGuiness J, Zhang D, Chung MC, Li D, Zhang C, Marconi C, Campaneria Y, Chardon-Robles J, Grippin A, Karachi A, Thomas N, Huang J, Milner R, Sahay B, Sawyer WG, Ligon JA, Silver N, Simon E, Cleaver B, Wynne K, Hodik M, Molinaro A, Guan J, Kellish P, Doty A, Lee JH, Carrera-Justiz S, Rahman M, Gatica S, Mueller S, Prados M, Ghiaseddin A, Mitchell DA, Sayour EJ. Mendez-Gomez HR, et al. Among authors: sayour ej. medRxiv [Preprint]. 2023 Mar 17:2023.03.12.23287108. doi: 10.1101/2023.03.12.23287108. medRxiv. 2023. Update in: Cell. 2024 May 9;187(10):2521-2535.e21. doi: 10.1016/j.cell.2024.04.003. PMID: 36993772 Free PMC article. Updated. Preprint.
RNA-LPAs were safe in acute/chronic murine GLP toxicology studies and immunologically active in client-owned canines with terminal gliomas. ...These data support the use of RNA-LPAs as novel tools to elicit and sustain immune responses against poorly immunogenic tum …
RNA-LPAs were safe in acute/chronic murine GLP toxicology studies and immunologically active in client-owned canines with terminal gl …
Contemporary RNA Therapeutics for Glioblastoma.
Melnick K, Dastmalchi F, Mitchell D, Rahman M, Sayour EJ. Melnick K, et al. Among authors: sayour ej. Neuromolecular Med. 2022 Mar;24(1):8-12. doi: 10.1007/s12017-021-08669-9. Epub 2021 Jun 8. Neuromolecular Med. 2022. PMID: 34101090 Free PMC article. Review.
RNA offers clear advantages over antigen-focused approaches but cannot often be directly administered due to biological instability. This review will focus on utilization of RNA dendritic cell vaccines and RNA nanoparticle therapies in the treatment of GBM. …
RNA offers clear advantages over antigen-focused approaches but cannot often be directly administered due to biological instability. …
Cancer Vaccine Immunotherapy with RNA-Loaded Liposomes.
Sayour EJ, Mendez-Gomez HR, Mitchell DA. Sayour EJ, et al. Int J Mol Sci. 2018 Sep 23;19(10):2890. doi: 10.3390/ijms19102890. Int J Mol Sci. 2018. PMID: 30249040 Free PMC article. Review.
Since RNA is inherently unstable, delivery systems have been developed to protect and deliver it to intended targets in vivo. In this review, we discuss liposomes as RNA delivery vehicles and their role as cancer vaccines....
Since RNA is inherently unstable, delivery systems have been developed to protect and deliver it to intended targets in vivo. In this …
Manipulation of Innate and Adaptive Immunity through Cancer Vaccines.
Sayour EJ, Mitchell DA. Sayour EJ, et al. J Immunol Res. 2017;2017:3145742. doi: 10.1155/2017/3145742. Epub 2017 Feb 6. J Immunol Res. 2017. PMID: 28265580 Free PMC article. Review.
Although peptide vaccines have shown tepid responses in a therapeutic setting with poor correlates for immune activity, RNA vaccines activate innate immune responses and have shown promising effects in preclinical and clinical studies based on enhanced DC migration. ...
Although peptide vaccines have shown tepid responses in a therapeutic setting with poor correlates for immune activity, RNA vaccines …
Personalized Tumor RNA Loaded Lipid-Nanoparticles Prime the Systemic and Intratumoral Milieu for Response to Cancer Immunotherapy.
Sayour EJ, Grippin A, De Leon G, Stover B, Rahman M, Karachi A, Wummer B, Moore G, Castillo-Caro P, Fredenburg K, Sarkisian MR, Huang J, Deleyrolle LP, Sahay B, Carrera-Justiz S, Mendez-Gomez HR, Mitchell DA. Sayour EJ, et al. Nano Lett. 2018 Oct 10;18(10):6195-6206. doi: 10.1021/acs.nanolett.8b02179. Epub 2018 Sep 27. Nano Lett. 2018. PMID: 30259750 Free PMC article.
In summary, we demonstrate widespread immune activation from tumor loaded RNA-NPs concomitant with inducible PD-L1 expression that can be therapeutically exploited. While immunotherapy remains effective for only a subset of cancer patients, combination therapy with systemi …
In summary, we demonstrate widespread immune activation from tumor loaded RNA-NPs concomitant with inducible PD-L1 expression that ca …
Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles.
Sayour EJ, De Leon G, Pham C, Grippin A, Kemeny H, Chua J, Huang J, Sampson JH, Sanchez-Perez L, Flores C, Mitchell DA. Sayour EJ, et al. Oncoimmunology. 2016 Nov 18;6(1):e1256527. doi: 10.1080/2162402X.2016.1256527. eCollection 2017. Oncoimmunology. 2016. PMID: 28197373 Free PMC article.
To circumvent the challenges of cellular immunotherapeutics, we developed clinically translatable nanoliposomes that can be combined with tumor-derived RNA to generate personalized tumor RNA-nanoparticles (NPs) with considerable scale-up capacity. ...RNA-NPs …
To circumvent the challenges of cellular immunotherapeutics, we developed clinically translatable nanoliposomes that can be combined with tu …
Fusobacterium is enriched in oral cancer and promotes induction of programmed death-ligand 1 (PD-L1).
Michikawa C, Gopalakrishnan V, Harrandah AM, Karpinets TV, Garg RR, Chu RA, Park YP, Chukkapallia SS, Yadlapalli N, Erikson-Carter KC, Gleber-Netto FO, Sayour E, Progulske-Fox A, Chan EKL, Wu X, Zhang J, Jobin C, Wargo JA, Pickering CR, Myers JN, Silver N. Michikawa C, et al. Among authors: sayour e. Neoplasia. 2022 Sep;31:100813. doi: 10.1016/j.neo.2022.100813. Epub 2022 Jul 11. Neoplasia. 2022. PMID: 35834946 Free PMC article.
Here, paired tumor and adjacent normal tissues from thirty-seven oral tongue squamous cell carcinoma (SCC) patients were subjected to 16S rRNA gene sequencing and whole exome sequencing (WES), in addition to RNA sequencing for tumor samples. We observed that Fusobacterium …
Here, paired tumor and adjacent normal tissues from thirty-seven oral tongue squamous cell carcinoma (SCC) patients were subjected to 16S rR …
Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas.
Flores C, Pham C, Snyder D, Yang S, Sanchez-Perez L, Sayour E, Cui X, Kemeny H, Friedman H, Bigner DD, Sampson J, Mitchell DA. Flores C, et al. Among authors: sayour e. Oncoimmunology. 2015 Jan 22;4(3):e994374. doi: 10.4161/2162402X.2014.994374. eCollection 2015 Mar. Oncoimmunology. 2015. PMID: 25949916 Free PMC article.
Adoptive cellular therapy (ACT) after lymphodepletive conditioning can induce dramatic clinical responses, but this approach has been largely limited to melanoma due to a lack of reliable methods for expanding tumor-specific lymphocytes from the majority of other solid cancers. W …
Adoptive cellular therapy (ACT) after lymphodepletive conditioning can induce dramatic clinical responses, but this approach has been largel …
17 results